HITGEN

HitGen OpenDEL™

Affordable Access to Billions of Novel Molecules & Data for AI/ML in Drug Discovery Research

HITGEN

OpenDEL™ – Fully Transparent Open Access

- **Access to**
  - Small Molecule Structures
  - Building Blocks
  - Scaffolds
  - DNA Codons
  - Synthetic Schemes
  - Selection Manual
- **No Structure Disclosure Fee**
- **No Compound IP License Fee**

OpenDEL™ to Help Your Research

- **For AI/ML:**
  - Post-selection DEL data for AI/ML
- **For Drug Discovery:**
  - Rapid and efficient target ligandability evaluation
  - Novel Hit discovery

Content of OpenDEL™

- 3 Billion Compounds
- 50 Encoded Libraries
- 10 2-Cycle Libraries
- 40 3-Cycle Libraries
- No 4-Cycle Libraries
- Physical Materials
- Selection Manual
- Synthetic Schemes
- Building Block lists
- DNA Codon lists

Chemistry Diversity

C-C Bond Formation

- Indole C3 alkylation
- Suzuki coupling
- Photoredox
- Sonogashira coupling

C-N Bond Formation

- Acylation
- Reductive Amination with Aldehyde
- Reductive Amination with Ketone
- Buchwald-Hartwig Cross Coupling
- SN_2/SN_{Ar}
- Sulfonylation

Functional Group Transformation

- NO_2 to Amine
- Azide to amine
- Amine to azide
- Halide to azide
- Halide to amine
- Halide to alkyne
- Halide to acid
- Halide to cyanide
- Aldehyde to alkyne
- Alkene to aldehyde
- Thioether oxidation

In-situ Heterocycle Formation

- Triazoles
- Imidazolindinone
- Pyridones
- 1,2,4-oxadiazole
- isoindolinone
- Benzimidazole
- Benzotriazole
- Indazolone
- 2-pyridinone

HITGEN

Building Block/Scaffold Diversity

Mono-functional group BBs: **>20,000**
Bi-functional group BBs: **>3,000**
Novel scaffolds: **>550**
BBs: amines, acids, aldehydes, boronates, protected amino acids, free amino acids, amino esters, diamines, acid-aldehydes, acid-aryl-halides, etc.

Physicochemical Property



	Average MW (Da)	MW<500 & AlogP<5	MW<550	MW<500	MW<450
2-Cycle DELs	414	88%	99.7%	95%	74%
3-Cycle DELs	484	62%	91.5%	66%	23%

OpenDEL™ Service

HitGen provides full technical support and/or on-demand services for the entire drug discovery process

OpenDEL™ Kit | OpenDEL™ Selection Manual | On-DNA Reference Compound | OpenDEL™ selection | Sequencing (NGS) | Data Analysis & Hit Proposal | Off-DNA Synthesis | Binding/ Functional Confirmation | Hit Expansion | ADMET & Other Profiling

OpenDEL™ Access Model

	OpenDEL™ Kits	OpenDEL™ Selection Manual	On-DNA Reference Compound	OpenDEL™ Selection	Sequencing (NGS)	Data analysis & Hit Proposal	Off-DNA Synthesis	Binding/ Functional Confirmation
OpenDEL™ Taster	√ 4 selection samples	√				√		
OpenDEL™ Standard	√ 10 selection samples	√				√		
OpenDEL™ Premium	√ 10 selection samples	√	√ (If having)	√	√	√		
OpenDEL™ Premium Plus	√ 10 selection samples	√	√ (If having)	√	√	√	√ Up to 10 compounds	√ Up to 10 compounds

Customer Testimonial

"HitGen has created one of the most exciting new DEL products. Septerna was initially attracted to the openness and flexibility with the OpenDEL model. And we have now successfully identified functionally validated hits for multiple GPCR targets from the OpenDEL libraries. Most importantly, the HitGen team has been a very open and collaborative partner throughout the process."

By Septerna, A US-based biotechnology company discovering and advancing novel small molecule medicines targeting G Protein-Coupled Receptors

About HitGen Inc.

HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.

Add: Building C2, No. 8 Huigu 1st East Road, Tianfu International Bio-Town, Shuangliu District, Chengdu, Sichuan, China 610200
Tel: +86 (28) 85197385 **Web:** www.hitgen.com
For business inquiry: bd@hitgen.com
For technical inquiry: opendel@hitgen.com